Annals of Hematology

, Volume 98, Issue 10, pp 2399–2405 | Cite as

Long-term follow-up of rituximab in treatment of chronic graft-versus-host disease—single center experience

  • Sebastian KlobuchEmail author
  • Daniela Weber
  • Barbara Holler
  • Matthias Edinger
  • Wolfgang Herr
  • Ernst Holler
  • Daniel Wolff
Original Article


Rituximab was recently described also as first-line therapy of chronic graft-versus-host disease (cGvHD). We retrospectively analyzed the efficacy and safety of all patients receiving rituximab for treatment of cGvHD between 2005 and 2016 at the Regensburg University transplant center with a median follow-up after rituximab therapy of 2.8 years. Responses of 29 allogeneic stem cell-transplanted patients (median age 49) with previous failure of response to steroids including one patient after donor lymphocyte infusion were assessed. Three months after rituximab application, the overall response rate was 31% (7% complete (n = 2) and 24% partial remission (n = 7)). At 12 months, overall survival was 72% (n = 21) and failure-free survival was 24% (n = 7). We further analyzed associations of rituximab response with clinical characteristics showing a higher response rate in steroid-dependent cGvHD patients (89% of 9 responding compared to steroid refractory patients (11% responding)). However, this difference was not statistically significant. Seven patients (24%) (including four lethal infectious complications) developed serious infections requiring hospitalization within 1–9 months after rituximab therapy exclusively in patients failing to respond to rituximab. In conclusion, rituximab appears to be an effective treatment of cGvHD especially in steroid dependent patients, but identification of biomarker predicting response will be crucial to avoid long-term infectious morbidity and mortality in non-responders.


Allogeneic stem cell transplantation Chronic graft-versus-host disease Rituximab 


Compliance with ethical standards


This work was funded by the german research foundation, collaborative research center 221, individual project B10 (Daniel Wolff).

Conflict of interest

Daniel Wolff received honoraria from Mallinckrodt, Novartis, Shire and Neovii. All other authors declare no conflict of interest.

Ethical approval

Because our study was a retrospective analysis, no additional ethical approval of the institutional committee was necessary.

Informed consent

Informed consent to receive rituximab was obtained from all individual participants included in the study.


  1. 1.
    Socié G, Ritz J (2014) Current issues in chronic graft-versus-host disease. Blood 124(3):374–384. CrossRefGoogle Scholar
  2. 2.
    Martin PJ, Storer BE, Inamoto Y, Flowers MED, Carpenter PA, Pidala J, Palmer J, Arora M, Jagasia M, Arai S, Cutler CS, Lee SJ (2017) An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease. Blood 130(3):360–367. CrossRefGoogle Scholar
  3. 3.
    Zeiser R, Blazar BR (2017) Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med 377(26):2565–2579. CrossRefGoogle Scholar
  4. 4.
    Sarantopoulos S, Ritz J (2015) Aberrant B-cell homeostasis in chronic GVHD. Blood 125(11):1703–1707. CrossRefGoogle Scholar
  5. 5.
    Sarantopoulos S, Stevenson KE, Kim HT, Cutler CS, Bhuiya NS, Schowalter M, Ho VT, Alyea EP, Koreth J, Blazar BR, Soiffer RJ, Antin JH, Ritz J (2009) Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood 113(16):3865–3874. CrossRefGoogle Scholar
  6. 6.
    Wang KS, Kim HT, Nikiforow S, Heubeck AT, Ho VT, Koreth J, Alyea EP, Armand P, Blazar BR, Soiffer RJ, Antin JH, Cutler CS, Ritz J (2017) Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease. Blood 130(26):2889–2899. CrossRefGoogle Scholar
  7. 7.
    Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D, Klickstein LB, Levin J, Miller K, Reynolds C, Macdonell R, Pasek M, Lee SJ, Ho V, Soiffer R, Antin JH, Ritz J, Alyea E (2006) Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 108(2):756–762. CrossRefGoogle Scholar
  8. 8.
    Kharfan-Dabaja MA, Mhaskar AR, Djulbegovic B, Cutler C, Mohty M, Kumar A (2009) Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis. Biol Blood Marrow Transplant 15(9):1005–1013. CrossRefGoogle Scholar
  9. 9.
    Mohty M, Marchetti N, El-Cheikh J et al (2008) Rituximab as salvage therapy for refractory chronic GVHD. Bone Marrow Transplant 41(10):909–911. CrossRefGoogle Scholar
  10. 10.
    Clavert A, Chevallier P, Guillaume T, Delaunay J, le Gouill S, Mahe B, Dubruille V, Gastinne T, Blin N, Moreau P, Mohty M (2013) Safety and efficacy of rituximab in steroid-refractory chronic GVHD. Bone Marrow Transplant 48(5):734–736. CrossRefGoogle Scholar
  11. 11.
    Arai S, Pidala J, Pusic I, Chai X, Jaglowski S, Khera N, Palmer J, Chen GL, Jagasia MH, Mayer SA, Wood WA, Green M, Hyun TS, Inamoto Y, Storer BE, Miklos DB, Shulman HM, Martin PJ, Sarantopoulos S, Lee SJ, Flowers MED (2016) A randomized phase II crossover study of Imatinib or rituximab for cutaneous sclerosis after hematopoietic cell transplantation. Clin Cancer Res 22(2):319–327. CrossRefGoogle Scholar
  12. 12.
    Arai S, Sahaf B, Narasimhan B, Chen GL, Jones CD, Lowsky R, Shizuru JA, Johnston LJ, Laport GG, Weng WK, Benjamin JE, Schaenman J, Brown J, Ramirez J, Zehnder JL, Negrin RS, Miklos DB (2012) Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood 119(25):6145–6154. CrossRefGoogle Scholar
  13. 13.
    Cutler C, Kim HT, Bindra B, Sarantopoulos S, Ho VT, Chen YB, Rosenblatt J, McDonough S, Watanaboonyongcharoen P, Armand P, Koreth J, Glotzbecker B, Alyea E, Blazar BR, Soiffer RJ, Ritz J, Antin JH (2013) Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. Blood 122(8):1510–1517. CrossRefGoogle Scholar
  14. 14.
    Malard F, Labopin M, Yakoub-Agha I, Chantepie S, Guillaume T, Blaise D, Tabrizi R, Magro L, Vanhove B, Blancho G, Moreau P, Gaugler B, Chevallier P, Mohty M (2017) Rituximab-based first-line treatment of cGVHD after allogeneic SCT. Results of a phase 2 study. Blood 130(20):2186–2195. CrossRefGoogle Scholar
  15. 15.
    Solomon SR, Sizemore CA, Ridgeway M, Zhang X, Smith J, Brown S, Holland HK, Morris LE, Bashey A (2015) Corticosteroid-free primary treatment of chronic extensive graft-versus-host disease incorporating rituximab. Biol Blood Marrow Transplant 21(9):1576–1582. CrossRefGoogle Scholar
  16. 16.
    Miklos D, Cutler CS, Arora M, Waller EK, Jagasia M, Pusic I, Flowers ME, Logan AC, Nakamura R, Blazar BR, Li Y, Chang S, Lal I, Dubovsky J, James DF, Styles L, Jaglowski S (2017) Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood 130(21):2243–2250. CrossRefGoogle Scholar
  17. 17.
    George L, George B, Gottlieb DJ, Hertzberg M, Fernandez-Peñas P (2012) Lack of efficacy of rituximab in refractory sclerodermatous chronic GVHD. Bone Marrow Transplant 47(5):737–738. CrossRefGoogle Scholar
  18. 18.
    Gillissen MA, de Jong G, Levie SE, Yasuda E, Bakker AQ, Evers LM, Pals ST, Huisman C, van Helden PM, Spits H, Hazenberg MD (2016) AML relapse after rituximab treatment for GvHD: crucial role for B cells in GvL responses. Bone Marrow Transplant 51(9):1245–1248. CrossRefGoogle Scholar
  19. 19.
    Gillissen MA, Kedde M, Gd J et al (2018) AML-specific cytotoxic antibodies in patients with durable graft-versus-leukemia responses. Blood 131(1):131–143. Google Scholar
  20. 20.
    Lee SJ, Wolff D, Kitko C, Koreth J, Inamoto Y, Jagasia M, Pidala J, Olivieri A, Martin PJ, Przepiorka D, Pusic I, Dignan F, Mitchell SA, Lawitschka A, Jacobsohn D, Hall AM, Flowers MED, Schultz KR, Vogelsang G, Pavletic S (2015) Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response criteria working group report. Biol Blood Marrow Transplant 21(6):984–999. CrossRefGoogle Scholar
  21. 21.
    Schoemans HM, Lee SJ, Ferrara JL et al (2018) EBMT-NIH-CIBMTR task force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transplant 53:1401–1415. CrossRefGoogle Scholar
  22. 22.
    Zaja F, Bacigalupo A, Patriarca F et al (2007) Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant 40(3):273–277. CrossRefGoogle Scholar
  23. 23.
    Olivieri J, Manfredi L, Postacchini L, Tedesco S, Leoni P, Gabrielli A, Rambaldi A, Bacigalupo A, Olivieri A, Pomponio G (2015) Consensus recommendations for improvement of unmet clinical needs--the example of chronic graft-versus-host disease: a systematic review and meta-analysis. Lancet Haematol 2(7):e297–e305. CrossRefGoogle Scholar
  24. 24.
    von Bonin M, Oelschlägel U, Radke J, Stewart M, Ehninger G, Bornhauser M, Platzbecker U (2008) Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab. Transplantation 86(6):875–879. CrossRefGoogle Scholar
  25. 25.
    Dubovsky JA, Flynn R, Du J et al (2014) Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest 124(11):4867–4876. CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Internal Medicine IIIUniversity Hospital RegensburgRegensburgGermany
  2. 2.Regensburg Center for Interventional ImmunologyUniversity Hospital RegensburgRegensburgGermany

Personalised recommendations